ReviewEndocrine reviews2014
Inhibin at 90: from discovery to clinical application, a historical review.
Review in Endocrine reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 3 syntheses or guidelines pooled it, 180 citations in OpenAlex.
- Iron overload disorders in adults: a comprehensive review of gonadal function, reproductive, and sexual health.Human reproduction update · 2026Pooled it
- Immunization Against Inhibin Promotes Fertility in Cattle: A Meta-Analysis and Quality Assessment.Frontiers in veterinary science · 2021Pooled it
- Follicle Stimulating Hormone is an accurate predictor of azoospermia in childhood cancer survivors.PloS one · 2017Pooled it
- Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial.Cardiovascular diabetology · 2019Trial
- Follistatins in glucose regulation in healthy and obese individuals.Diabetes, obesity & metabolism · 2019Trial
- Regulation of the activins-follistatins-inhibins axis by energy status: Impact on reproductive function.Metabolism: clinical and experimental · 2018Trial
- Screening and Preliminary Identification of Inhibin α Subunit-Specific Nanobodies Through High-Throughput Sequencing Combined with Mass Spectrometry.Animals : an open access journal from MDPI · 2026Article
- Adropin: A New Regulator of Testicular Function-What Do We Know So Far?International journal of molecular sciences · 2026Review
- Impact of acute anorexia nervosa and of short-/long-term recovery after refeeding on the hormonal profiles of activin A, GDF-15 and follistatins.Molecular psychiatry · 2026Article
- What we could not have known: ovarian cycles, follicle development, and the signature of life.Molecular human reproduction · 2026Review
- A challenging hypothesis: can a SNP changing cysteine 1 in the α inhibin pro-domain induce reproduction-linked PCOS phenotypes?Frontiers in endocrinology · 2026Review
- Functional data analysis of FSH and inhibin B levels in four ovulatory cycles shows a changing oscillatory interaction during the follicular phase.Frontiers in endocrinology · 2026Article
- Key role for inhibins in effective T cell activation, migration and Th17 differentiation.FEBS open bio · 2026Article
- Familial Von Hippel-Lindau Disease: A Case Series of Cerebral Hemangioblastomas with MRI, Histopathological, and Genetic Correlations.Life (Basel, Switzerland) · 2025Article
- Potential role of kisspeptin in the estradiol-induced modulation of inhibin subunit gene expression: Insights from in vivo rat models and hypothalamic cell models.Endocrine journal · 2025Article
- Activin Actions in Adipocytes.The Journal of clinical endocrinology and metabolism · 2025Review
- Article
- Activins and Inhibins in Cardiovascular Pathophysiology.Biomolecules · 2024Review
- Inhibin subunit beta B (INHBB): an emerging role in tumor progression.Journal of physiology and biochemistry · 2024Review
- Maternal TGF-β ligand Panda breaks the radial symmetry of the sea urchin embryo by antagonizing the Nodal type II receptor ACVRII.PLoS biology · 2024Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
When it was initially discovered in 1923, inhibin was characterized as a hypophysiotropic hormone that acts on pituitary cells to regulate pituitary hormone secretion. Ninety years later, what we know about inhibin stretches far beyond its well-established capacity to inhibit activin signaling and suppress pituitary FSH production. Inhibin is one of the major reproductive hormones involved in the regulation of folliculogenesis and steroidogenesis. Although the physiological role of inhibin as an activin antagonist in other organ systems is not as well defined as it is in the pituitary-gonadal axis, inhibin also modulates biological processes in other organs through paracrine, autocrine, and/or endocrine mechanisms. Inhibin and components of its signaling pathway are expressed in many organs. Diagnostically, inhibin is used for prenatal screening of Down syndrome as part of the quadruple test and as a biochemical marker in the assessment of ovarian reserve. In this review, we provide a comprehensive summary of our current understanding of the biological role of inhibin, its relationship with activin, its signaling mechanisms, and its potential value as a diagnostic marker for reproductive function and pregnancy-associated conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.